Novel anti-inflammatory mechanisms of the Glucocorticoid Receptor
糖皮质激素受体的新抗炎机制
基本信息
- 批准号:24920688
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:德国
- 项目类别:Research Grants
- 财政年份:2006
- 资助国家:德国
- 起止时间:2005-12-31 至 2010-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Glucocorticoid hormones (GC) are potent anti-inflammatory agents, which are widely used in therapy. However, their usefulness is limited by catabolic side effects that often occur during GC treatment. They strongly compromise the quality of life of the patients and cause additional treatment costs in the order of hundreds of million ¿. It is therefore of great importance to understand the molecular mechanisms by which GC exert their anti-inflammatory as well as their catabolic action in order to develop new and more specific drugs and treatments. The currently accepted view in the field attributes the anti-inflammatory action of GC to mechanisms which do not depend on DNA binding by the glucocorticoid receptor (GR), whereas side effect are believed to be mediated by dimerization-dependent DNA-binding. However, in unpublished studies we showed that in murine models for contact allergy and sepsis, DNA binding of the GR is required for the immune suppressive activity of GC. Mice lacking the dimerization-induced DNA binding function of the GR (GRdim mice) do not react to GC in these disease paradigms. By expression profiling and RT-PCR analysis of macrophages derived from GRdim mice, we identified genes that are regulated by GC in wild type, but not in GRdim cells. These genes are putative candidates for the mechanisms involved in mediating GCinduced anti-inflammatory action. We intend to analyze the function of these GC modulated genes by cell culture assays, in tissues of disease models and in in vivo models of these diseases. We further plan to study the regulation of these genes by the dimerizing GR in the context of their promoters, and of interacting factors that are required for this regulation. We hope to thus identify novel pathways involved in GC function. This could lead to new models for improved therapies and to the identification of novel anti-inflammatory drug targets.
糖皮质激素(GC)是一种有效的抗炎药物,广泛应用于治疗。然而,它们的有用性受到GC治疗期间经常发生的分解代谢副作用的限制。它们严重损害了患者的生活质量,并导致数亿美元的额外治疗费用。因此,了解GC发挥其抗炎作用以及其分解代谢作用的分子机制以开发新的和更具体的药物和治疗是非常重要的。本领域目前接受的观点将GC的抗炎作用归因于不依赖于糖皮质激素受体(GR)的DNA结合的机制,而副作用被认为是由二聚化依赖性DNA结合介导的。然而,在未发表的研究中,我们发现在接触性变态反应和脓毒症的小鼠模型中,GR的DNA结合是GC的免疫抑制活性所必需的。缺乏GR二聚化诱导的DNA结合功能的小鼠(GRdim小鼠)在这些疾病范例中不对GC反应。通过表达谱分析和RT-PCR分析来自GRdim小鼠的巨噬细胞,我们确定了在野生型中受GC调控的基因,但在GRdim细胞中不受GC调控。这些基因是参与介导GC诱导的抗炎作用的机制的假定候选者。我们打算通过细胞培养试验,在疾病模型的组织和这些疾病的体内模型中分析这些GC调节基因的功能。我们进一步计划研究这些基因的调节,由二聚GR在其启动子的背景下,和相互作用的因素,这是必要的调节。因此,我们希望确定参与GC功能的新途径。这可能会导致新的模型,以改善治疗和识别新的抗炎药物的目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Professor Dr. Jan Tuckermann其他文献
Professor Dr. Jan Tuckermann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Professor Dr. Jan Tuckermann', 18)}}的其他基金
A novel function of cyclin-dependent kinase 5 (Cdk5) in bone integrity - a potential therapeutic target to treat osteoporosis
细胞周期蛋白依赖性激酶 5 (Cdk5) 在骨完整性中的新功能 - 治疗骨质疏松症的潜在治疗靶点
- 批准号:
338458780 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Research Grants
Molecular and genetic characterization of the Sorting Nexin 10 R51Q mutation and other mutations, causing osteopetrosis in infancy in Palestinian clans
导致巴勒斯坦部族婴儿期骨硬化症的分选 Nexin 10 R51Q 突变和其他突变的分子和遗传特征
- 批准号:
279908667 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Research Grants
GR-AMPK - Crosstalk of Glucocorticoid Receptor and AMP-induced Kinase in macrophages during inflammation and tissue repair
GR-AMPK - 炎症和组织修复过程中巨噬细胞中糖皮质激素受体和 AMP 诱导激酶的串扰
- 批准号:
283865434 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Research Grants
Cell type specific action of glucocorticoids in inflammation and bone integrity of rheumatoid arthritis
糖皮质激素在类风湿关节炎炎症和骨完整性中的细胞类型特异性作用
- 批准号:
168861521 - 财政年份:2010
- 资助金额:
-- - 项目类别:
Priority Programmes
Glucocorticoid-coordinated regulation of satellite cells and their microenvironment in skeletal muscle
糖皮质激素对骨骼肌卫星细胞及其微环境的协调调节
- 批准号:
505870049 - 财政年份:
- 资助金额:
-- - 项目类别:
Research Grants
相似国自然基金
基于spA-Gel负载Anti-HMGB1原位靶向免疫耐受的猪胰岛类器官移植研
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
肺癌外周血淋巴细胞亚群预测anti-PD1/PDL1疗效的鉴定及应用研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
TKIs氘代化修饰通过促进HCC铁死亡增强免疫原性并增敏anti-PD-1治疗的机制研究
- 批准号:JCZRQN202500319
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
构建α-突触核蛋白特异性CAR-Treg治疗抗NMDAR脑炎的研究
- 批准号:2025JJ80620
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
Anti-MDA5阳性皮肌炎病人的NK细胞数量与功能改变在间质性肺疾病中的作用与机制研究
- 批准号:MS25H100014
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
特发性膜性肾病血清标志物anti-PLA2R-IgG4检测方法的建立及临床应用
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
经 anti-GPC3 修饰的外泌体靶向递送索拉非尼与放疗联合诱
导肝细胞癌铁死亡的研究
- 批准号:2024JJ9608
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
CCL2介导PGK1的O-GlcNAc糖基化修饰诱导CAFs代谢重编程促进头颈癌anti-PD-1免疫治疗耐药的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
千金藤素通过自噬损伤导致的免疫原性细胞死亡促进 anti-PD1 治疗MSS 型结直肠癌的疗效与机制研究
- 批准号:
- 批准年份:2024
- 资助金额:10.0 万元
- 项目类别:省市级项目
周细胞 ZEB1/SPP1 旁分泌轴招募 MDSCs 诱导
卵巢癌 anti-PD1/PD-L1 疗法耐药的机制研究
- 批准号:Y24H310009
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
相似海外基金
Targeting Nuclear HSF1 as a Novel Anti-HCMV Strategy
靶向核 HSF1 作为一种新型抗 HCMV 策略
- 批准号:
10656697 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Evaluating a novel, orally-active TREM2-targeting drug in AD
评估一种新型口服活性 TREM2 靶向药物治疗 AD 的效果
- 批准号:
10735206 - 财政年份:2023
- 资助金额:
-- - 项目类别:
A Novel Assay to Improve Translation in Analgesic Drug Development
改善镇痛药物开发转化的新方法
- 批准号:
10726834 - 财政年份:2023
- 资助金额:
-- - 项目类别:
HLA-E and NKG2A define a novel immune checkpoint axis in non-muscle-invasive bladder cancer
HLA-E 和 NKG2A 定义了非肌层浸润性膀胱癌的新型免疫检查点轴
- 批准号:
10587009 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
- 批准号:
10696749 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
特发性肺纤维化新型治疗剂的临床前开发
- 批准号:
10696538 - 财政年份:2023
- 资助金额:
-- - 项目类别:
GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: A Novel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular
缓释 PNA5 的 GMP 生产和 IND 启用研究:一种治疗阿尔茨海默氏病相关痴呆和血管性认知障碍患者认知障碍的新疗法
- 批准号:
10819329 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Novel Bioresorbable Vascular Scaffolds with Uniform Biodegradation
具有均匀生物降解性的新型生物可吸收血管支架
- 批准号:
10930188 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigation of the role of a novel molecule ZAIP in the regulation of anti-inflammation and inflammatory diseases
新型分子ZAIP在抗炎和炎症疾病调节中的作用研究
- 批准号:
23H02701 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
PARP1 and PARylation as novel effectors of gut inflammation
PARP1 和 PARylation 作为肠道炎症的新型效应物
- 批准号:
10679646 - 财政年份:2023
- 资助金额:
-- - 项目类别: